Bharat Parenterals Ltd Share Price – BSE

Pharmaceuticals, Small Cap

Net Loss of Bharat Parenterals reported to Rs 7.24 crore in the quarter ended September 2025 as against net loss of Rs 7.50 crore during the previous quarter ended September 2024. Sales declined 9.79% to Rs 64.62 crore in the quarter ended September 2025 as against Rs 71.63 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 12 November 2025.

Powered by Capital Market - Live News

Bharat Parenterals announced that the Annual General Meeting(AGM) of the company will be held on 26 September 2025.

Powered by Capital Market - Live News

Bharat Parenterals announced that its subsidiary, Innoxel Lifesciences, has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its finished dosage manufacturing facility in Vadodara, Gujarat.

This follows the successful completion of the U.S. FDA inspection conducted from April 28 to May 2, 2025. The facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms - Liquid Injectables and Oral Liquids.

With the receipt of the EIR, Innoxel Lifesciences has also received acceptance of the site for commercial operations for the product(s) under inspection.

This milestone reinforces Innoxel's commitment to global quality benchmarks and enhances its capability to supply high-quality pharmaceutical products to regulated markets, such as United States and the European Union.

Powered by Capital Market - Live News